TITLE

Elan Corp. Injects $300 Million Into Market

AUTHOR(S)
Hahn, Tamar
PUB. DATE
June 1999
SOURCE
Private Placement Letter;06/07/99, Vol. 17 Issue 23, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that Elan Corp. PLC is in the market with $300 million transaction. Maturity of the subordinated notes; Business operation of Elan; Sales reported by Elan for 1998.
ACCESSION #
1953436

 

Related Articles

  • Elan Contemplates Splitting Up its Drug Delivery Arm. Sheridan, Cormac // BioWorld International;4/21/2010, Vol. 15 Issue 16, p1 

    The article reports that Elan Corp. plc is considering spinning out its drug delivery unit, Elan Drug Technologies, into a separately listed company in 2010. As disclosed, the Dublin, Ireland-based company is considering the public markets as a source of additional investment. The company also...

  • Elan to Sell Anti-Fungal Drug to Enzon for $370 Million.  // Chemical Market Reporter;10/7/2002, Vol. 262 Issue 12, p4 

    Reports that U.S. -based Elan Corp. has sell its rights to Enzon Inc. for 370 million dollar for an antifungal drug called Abelcet. Increase in the share price of Elan; Revenue generated by Elan in the year 2001; Decrease in research expenditures; Improvement in the liquidity of Elan.

  • Elan completes sale of Zonegran to Eisai.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p21 

    Reports on the sale of Zonegran, an anti-epileptic drug, from Elan Corp. to Eisai Inc. Terms of the agreement; Details on the marketing approval of the drug; Use of the drug to treat seizures and migraines.

  • FDA lists drugs under scrutiny for safety. DeArment, Alaric // Drug Store News;9/22/2008, Vol. 30 Issue 11, p6 

    The article reports on the released of a list of 20 drugs under review for possible issues by the U.S. Food and Drug Administration (FDA). These include Cymbalta from Eli Lilly & Co. with U.S. sales of $1.84 billion in 2007, and Tysabri from Elan Corp. PLC with global sales $342.9 million in...

  • Earnings Roundup.  // BioWorld Today;7/25/2008, Vol. 19 Issue 144, p3 

    The article reports that Elan Corp. plc of Dublin, Ireland reported $245.6 million in total revenue for the second quarter of 2008. An increase in sales of Tysabri, the multiple sclerosis drug partnered with Cambridge, Massachusetts-based Biogen Idec Inc., contributed to the financial...

  • Sales Likely to Soar For New MS Drug. Webb, Marion // San Diego Business Journal;12/6/2004, Vol. 25 Issue 49, p1 

    The article reports on sales forecasting for the new multiple sclerosis (MS) drug Tysabri. Analysts believe that Elan Corp. and Biogen Idec Inc.'s newly approved multiple sclerosis drug Tysabri could generate sales of $3.5 billion annually. Tysabri is slated as the first drug to be manufactured...

  • Smiling Irish eyes. Gopal, Kevin // Pharmaceutical Executive;Sep97, Vol. 17 Issue 9, p40 

    Provides an overview on the strong financial performance of Ireland-based Elan Corp. Transition of the company from a licensing and contract manufacturing operation to a biopharmaceutical firm; Rise of Elan's product sales; Expansion plans of the company.

  • Another drug approved as adjunctive therapy for seizures. MAill-Lewis, Jillene // Drug Topics;4/17/2000, Vol. 144 Issue 8, p34 

    Introduces antiepileptic drug Zonisamide or Zonegran marketed by Elan Pharmaceuticals company. Mechanism of action of the drug; Factors that can limit its usefulness.

  • Elan Sells $850M in HY. Sheahan, Matthew // High Yield Report;5/27/2013, p51 

    The article reports on the decision of Irish biotechnology firm Elan to increase its loan offering to 850 million U.S. dollars in May 2013.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics